Reminder: Corporate Access: ARGX/UCB Sep 14th Belgian Field Trip to Meet Management

Research evidence excerpt

Reminder: Corporate Access: ARGX/UCB Sep 14th Belgian Field Trip to Meet Management

Equity Capital Markets and strategic advisory transactions in the European life sciences

industry. He holds a B.Sc. in Life Science & Technology from the University of Groningen

and a Master of Engineering Management from Duke University.

•• Peter Ulrichts is the Chief Scientific Officer at argenx and joined the company in 2010.

In this role, he oversees the development of all clinical and pre-clinical compounds

within argenx’s pipeline. Peter joined the company as a research scientist where he was

involved in the development of various therapeutic antibodies for the treatment of

cancer and autoimmune diseases. While at argenx, he headed the development of

argenx’s FcRn antagonist efgartigimod until the first-in-human study, after which he

transitioned to become the lead scientist of the efgartigimod program. Peter holds a

B.S. in Chemistry from KU Leuven as well as an M.S. in Biotechnology and Ph.D. in

Immunology, both from the University of Ghent (Belgium).

European Pharmaceuticals, Biotechnology & Life Sciences

James Gordon Charles Pitman-King, CFA

+44 (0)20 7116 2784 +44 (0)20 3134 6023

Barclays, UK Barclays, UK

This event is intended for Barclays institutional investor clients only. This event is strictly and solely

for the benefit of the intended recipients. Please do not forward this invitation to any other party

without written consent from Barclays Research. Barclays' Investment Bankers are prohibited from

attending this event. Participant comments are not for attribution.

If your firm is in-scope for research unbundling under MiFID II and you require further information

regarding pricing to participate in this Barclays Research content event, please contact your sales